North China Pharmaceutical Group
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
| Website | ncpc.com.cn |
|---|---|
North China Pharmaceutical Group Corp. (NCPC), (
Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million.[1]
Organization
NCPC has 29 subsidiaries, among which North China Pharmaceutical Co., Ltd. is a listed company at Shanghai Stock Exchange with 59.87% of shares held by NCPC. NCPC is one of the four groups of the candidate enterprises approved by the China Securities Regulatory Commission for overseas listing. Cooperating with foreign companies and institutions, NCPC has established 16 joint ventures.
Products
NCPC currently produces[Hepatitis B Vaccine (CHO) on the market.
R&D
Through its independent research and development, NCPC was the first in China to succeed in developing dozens of new products such as
drugs screening, combinatorial chemical
technology and modern biotechnologies.
See also
References
External links
- North China Pharmaceutical Group Corp (in English and Chinese)
